There has been a new development in the native vaccine candidate based on virus-like particles (VLP). Industry and Technology Minister Mustafa Varank announced that the second doses have started to be administered in the Phase 2 phase of the VLP vaccine candidate. Minister Varank, who also informed that the first doses of Phase 2 were completed, underlined that no side effects were observed in the first doses.
Minister Varank attended the SATEM Sinop Biomass Power Plant Opening and Sinop Fisheries Operation, Shocking and Storage Facility Groundbreaking Ceremony in Sinop.
Sinop Governor Erol Karaömeroğlu, AK Party Sinop Deputy Nazım Maviş, Sinop Mayor Barış Ayhan, KOSGEB President Hasan Basri Kurt, Northern Anatolia Development Agency General Secretary Serkan Genç and AK Party Sinop Provincial President Uğur Giresun were also present at the ceremony.
INNOVATIVE VLP VACCINE
Speaking at the ceremony, Varank shared an important development in the fight against the Covid-19 epidemic. Noting that they are carrying out vaccine development studies under the roof of TÜBİTAK COVID-19 Turkey Platform, Varank said, "One of them is our VLP vaccine candidate based on a very innovative technology."
PASSED TO THE SECOND DOSAGE
Reminding that he also volunteered in the first human trials of the VLP vaccine, Varank said, “We passed the Phase 26 phase of the VLP vaccine on June 2. In Phase 2, the first dose vaccinations were completed, the second doses started to be administered.“ He said.
THE LINE IS PHASE 3
Underlining that no side effects have been observed in the vaccination so far, Varank said, "After the second doses are administered and the results from the volunteers are evaluated, we will hopefully move on to Phase 3, which is the final stage."
THE WORLD WILL BE HEALED
Varank continued as follows: If all processes are completed positively, we will have our native VLP vaccine. We will be making a contribution to the fight against the scourge of Covid-19 from Turkey to the whole world.
IN WHO LIST
The vaccine candidate, which is one of the few in the world and developed with the only VLP technology within the scope of the TUBITAK COVID-19 Turkey Platform, was included in the list of Covid-30 vaccine candidates of the World Health Organization (WHO) on March 19. Phase 2 study of native VLP vaccine candidate prepared according to British variant.
USES 4 STRUCTURAL PROTEINS
In VLP-type vaccines, the developed virus-like particles mimic the virus in a non-infectious way. While these particles evoke an immune response, they do not cause disease. Another feature of the domestic vaccine candidate is that, unlike other VLP vaccines, all 4 structural proteins of the virus are used as vaccine antigens.
APPLIED IN 3 HOSPITALS
Prof. from METU. Dr. The Phase-2 phase of the VLP vaccine candidate, developed as a result of the joint project of Mayda Gürsel and İhsan Gürsel from Bilkent University, is carried out at Ankara Oncology Training and Research Hospital, Kocaeli University Hospital and Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital.
WHO IS VOLUNTARY?
Those between the ages of 18-59, who do not have serious chronic diseases, have not had a coronavirus before and have not received another Covid-19 vaccine.